Elsevier

European Journal of Cancer

Volume 42, Issue 14, September 2006, Pages 2374-2381
European Journal of Cancer

Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis

https://doi.org/10.1016/j.ejca.2006.01.061Get rights and content

Abstract

Colorectal carcinogenesis is initiated mainly by aberrant activation of the Wnt signaling pathway, caused by mutation of either APC or β-catenin (CTNNB1) gene. Poly(ADP-ribose) polymerase-1 (PARP-1) is a highly conserved nuclear enzyme, which binds tightly to DNA and plays a role in DNA repair, recombination, proliferation and genomic stability. It has recently been shown that PARP-1 is a novel co-activator of TCF-4/β-catenin-evoked gene transactivation and may play a role in colorectal carcinogenesis. The aim of this study was to examine the PARP-1 expression and determine whether it is correlated with the expression of β-catenin and its target genes such as c-myc, cyclin D1 and matrix metalloproteinase (MMP)-7 in the early stage of sporadic colorectal carcinogenesis. Using the semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), 91 colorectal tumours, including 65 adenomas and 26 submucosal (pT1) cancers, were analysed for the expression of PARP-1, β-catenin, c-myc, cyclin D1 and MMP-7. Immunohistochemical analysis of PARP-1 and β-catenin was also performed. PARP-1 mRNA overexpression was detected in 64 (70.3%) of the 91 tumours. PARP-1 overexpression was significantly correlated with tumour size and histopathology. Overexpression of β-catenin, c-myc, cyclin D1 and MMP-7 mRNA expression was observed in 39.6%, 78.0%, 83.5% and 72.5% of the 91 tumours, respectively. PARP-1 overexpression was correlated significantly with overexpression of β-catenin, c-myc, cyclin D1 and MMP-7. Correlation of PARP-1 expression with β-catenin overexpression was also demonstrated by immunohistochemistry. The results suggest that PARP-1, in conjunction with β-catenin, c-myc, cyclin D1 and MMP-7, plays an important role in the early stage of colorectal carcinogenesis.

Introduction

Colorectal cancer is one of the most common human malignancies in the world. Although alternative pathways exist, it is generally accepted that most colorectal carcinomas arise in pre-existing adenomas.1

Aberrant transactivation of T cell factor (TCF)-4-regulated genes by β-catenin plays a key role in colorectal carcinogenesis.1 APC dysfunction or abnormalities of the β-catenin gene result in cytoplasmic accumulation of unphosphorylated β-catenin. This stabilized β-catenin protein translocates into the nucleus where, it modulates gene transcription by interacting with TCF-4, resulting in transcriptional activation of target genes such as c-myc, cyclin-D1 and matrix metalloproteinase (MMP)-7 (matrilysin).2 Thus, the β-catenin/TCF-4 complex and its associated molecules appear to be candidates for targets of molecular therapy against colorectal cancer. In this regard, it is notable that poly(ADP-ribose) polymerase-1 (PARP-1) was recently identified as a novel co-activator of TCF-4/β-catenin-evoked gene transactivation.3

PARP-1 is a highly conserved nuclear enzyme that binds tightly to DNA and plays a role in DNA repair, recombination, proliferation and genomic stability.4, 5, 6 Although PARP-1 has been thought to play a protective role against carcinogenesis, no mutation or loss of heterozygosity (LOH) of the PARP-1 gene has been reported in clinical cancer tissues. On the other hand, overexpression of PARP-1 has been reported in various human malignancies, such as malignant lymphoma,7 breast carcinoma,8 Ewing’s sarcoma,9 hepatocellular carcinoma10 and endometrial carcinoma.11 Importantly, aberrant poly(ADP-ribose) metabolism, including enhanced PARP activity and poly(ADP-ribose) synthesis, has been shown by biochemical and immunohistochemical analyses in human colon adenoma and carcinoma.12

Recently, Idogawa and colleagues3 reported that PARP-1 physically interacted with TCF-4 and augmented the transcriptional activity of the β-catenin/TCF-4 complex. Knockdown of PARP-1 by RNA interference (RNAi) significantly suppressed both transcriptional activity and proliferation of colorectal cancer cells. PARP-1 was strongly expressed in nuclei of adenoma cells in the large intestine of all 10 patients with familial adenomatous polyposis (FAP) analysed and in the small and large intestines of Min mice. Notably, the expression pattern of PARP-1 in adenoma cells completely parallelled that of accumulated β-catenin protein. Therefore, the expression patterns and functional properties of PARP-1 suggest that PARP-1 plays a role in colorectal carcinogenesis.3, 12 PARP-1 overexpression has been detected in 23 (82.1%) of 28 sporadic colorectal carcinoma tissues.3 Although enhanced PARP-1 activity and poly(ADP-ribose) synthesis have been reported in a small number of sporadic colon adenoma tissues,12 it is not known whether PARP-1 overexpression is correlated with β-catenin in sporadic colorectal adenoma.

In an attempt to address these issues, we investigated the expression of PARP-1, β-catenin, c-myc, cyclin D1 and MMP-7 in 91 early colorectal tumour tissues, including 65 adenoma tissues and 26 cancer tissues with submucosal invasion (pT1), by using the semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). We further analysed immunohistochemically the expression of PARP-1 and β-catenin.

Section snippets

Patients and tissue samples

Ninety-one paired specimens of colorectal tumour and non-tumour tissues were obtained by polypectomy or surgical treatment. These tumour samples consisted of 65 adenomas and 26 adenocarcinomas with submucosal invasion (pT1 in the TNM classification of the Union International Contre Cancer) (Table 1). Additionally, seven hyperplastic polyp tissues were obtained by endoscopy. Each tissue specimen was divided into two pieces. For total RNA extraction, one sample was immediately frozen in liquid

PARP-1 and β-catenin mRNA expression in colorectal tumour tissues

To perform semi-quantitative RT-PCR analysis, the ranges of linear amplification for each target gene and for the control GAPDH gene were examined. The optimal number of PCR cycles and optimal mixing ratios of primers were determined. The expression of PARP-1 and β-catenin mRNA in 91 colorectal tumour tissues was examined. Fig. 1 shows the representative results. PARP-1 mRNA expression was detected in 64 (70.3%) of the 91 colorectal tumour tissues but was only faintly detected in adjacent

Discussion

The issue that we addressed in this study was the expression of PARP-1 and its relationship with the expression of β-catenin and its target genes, such as c-myc, cyclin D1 and MMP-7, in the early stage of colorectal carcinogenesis. The reason why we chose pT1 cancer is that it represents the early stage of colorectal cancer.

PARP-1 mRNA overexpression was detected in 64 (70.3%) of the 91 colorectal adenoma and pT1 cancer tissues but was only faintly detected in adjacent non-tumour tissues and

Ethics approval statement

An informed consent was obtained from each patient and the institutional review committee approved this study.

Conflict of interest statement

None declared.

Acknowledgements

This study was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (H.Y. and K.I.) and Grants-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan (H.Y. and K.I.).

References (19)

There are more references available in the full text version of this article.

Cited by (105)

  • Clonality and timing of relapsing colorectal cancer metastasis revealed through whole-genome single-cell sequencing

    2022, Cancer Letters
    Citation Excerpt :

    Inside each clade, cells did not group according to their sampling location, which suggests a lack of spatial genomic structure within the sampled regions. Notably, 12 non-synonymous SNVs appear to be clonal (i.e., they are shared by all sampled cells), including mutations in APC, TP53 as well as several others affecting genes associated with increased tumor growth and poor prognosis in CRC and multiple cancer types, such as IL23R [33], PARP1 [34], and PSMA7 [35]. Moreover, our results suggest that the relapse population arose from one of the two major liver metastatic lineages, sharing with it 241 mutations, including five non-synonymous changes, OR2T3 V117L, STXBP5L P783S, TBXT A381T, COL1A2 G592S, and MEIOC E538G.

View all citing articles on Scopus
View full text